Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim

Copenhagen, May 11, 2017 – Zealand Pharma A/S (“Zealand”) and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development of obesity in preclinical models, suggesting its potential use in treating obesity and obesity-related comorbidities. Zealand and Boehringer Ingelheim will jointly present these data at the Keystone Symposia `Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism` on Friday May 12 in Copenhagen, Denmark.